The ACR and SBI took issue with a recent study on the long-term mental anguish caused by false-positives from mammograms.
A recent study reporting the long-term mental anguish in women who obtain false-positives from mammograms should be taken with a grain of salt, say the American College of Radiology (ACR) and the Society of Breast Imaging (SBR). The study findings, published earlier this month in the Annals of Family Medicine, stated that false-positive findings on screening mammography cause long-term harm.
Researchers from Denmark surveyed 454 women who had received abnormal mammography findings following screening over one year. Researchers recruited two women with normal results for each woman who had abnormal results, all from the same day and same clinic. The women completed a validated questionnaire, the Consequences of Screening in Breast Cancer, at baseline, one, six, 18, and 36 months. The questionnaire covers 12 psychosocial outcomes.
The researchers found that six months after the final diagnosis, women who received false-positive findings reported “changes in existential values and inner calmness as great as those reported by women with a diagnosis of breast cancer.” Three years later, these women reported “greater negative psychosocial consequences compared with women who had normal findings in all 12 psychosocial outcomes.”
The study authors concluded that the false-positive findings had long-term implications on women’s psychological health.
The ACR and SBI questioned the methodology of the study, citing irregularities in the analysis, such as if the women with false-positive findings also had a family history of breast cancer, what further testing was done, and where the women completed the survey (at home or at the clinic).
“Anxiety regarding inconclusive test results is real and only natural,” the groups said in a release. “Physicians continue to refine the reporting process to ensure that patients receive results as quickly as possible. Attention to women’s feelings associated with test results is, and should be, a concern for those who provide this care.”
The organizations emphasized that the benefits of breast cancer screening outweigh potential harm.
FDA Clears Updated AI Platform for Digital Breast Tomosynthesis
November 12th 2024Employing advanced deep learning convolutional neural networks, ProFound Detection Version 4.0 reportedly offers a 50 percent improvement in detecting cancer in dense breasts in comparison to the previous version of the software.
Is the Kaiser Score More Effective than BI-RADS for Assessing Contrast-Enhanced Mammography and MRI?
October 14th 2024For women with breast-enhanced masses, Kaiser scoring (KS) demonstrated a 20 percent higher AUC than BI-RADS classification for contrast-enhanced mammography (CEM) and was comparable to KS for breast MRI.
FDA Clears New Features in AI-Powered Mammography Software Suite
October 11th 2024Therapixel’s MammoScreen suite has received 510(k) FDA clearances for a breast density assessment feature and updated software that includes automated pre-reporting, which reportedly expedites reporting of mammography findings.